JP2003089652A - Anti oral cavity candidiasis composition - Google Patents
Anti oral cavity candidiasis compositionInfo
- Publication number
- JP2003089652A JP2003089652A JP2001286088A JP2001286088A JP2003089652A JP 2003089652 A JP2003089652 A JP 2003089652A JP 2001286088 A JP2001286088 A JP 2001286088A JP 2001286088 A JP2001286088 A JP 2001286088A JP 2003089652 A JP2003089652 A JP 2003089652A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- essential
- lavender
- candidiasis
- oral cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は精油またはその成分
を１種類以上有効成分として含有する、口腔カンジダ症
の予防および治療に用いることができる抗口腔カンジダ
症医薬組成物および飲食品に関する。TECHNICAL FIELD The present invention relates to an anti-oral candidiasis pharmaceutical composition and a food or drink which can be used for the prevention and treatment of oral candidiasis, containing one or more essential oils or their components as active ingredients.
【0002】[0002]
【従来の技術】表在性真菌症の代表的なもののひとつに
カンジダ症がある。カンジダ症は口腔カンジダ症、食道
・腸管カンジダ症、外膣腔カンジダ症などの疾患がカン
ジダ属真菌の感染によって引き起こされるものである。
とりわけ、口腔カンジダ症は、エイズ患者などの免疫不
全患者の増加にともなって最近顕著に多くなっている。
従来、口腔カンジダ症に対しては、アンホテリシンＢの
ような抗生物質、アゾールのような合成抗真菌剤などの
ドライシロップ剤、ゲル剤が開発されているが、耐性
菌、更に元来薬剤耐性のカンジダ・グラブラータなどの
菌種の出現と増加などにより新しい治療法が求められて
いる状況である。特に免疫能が極度に低下した患者に適
用が可能な療法はいまだ確立されていない。2. Description of the Related Art Candidiasis is one of the typical superficial mycoses. Candidiasis is a disease in which oral candidiasis, esophageal / intestinal candidiasis, external vaginal candidiasis, and the like are caused by infection with a Candida fungus.
In particular, oral candidiasis has been remarkably increasing recently with the increase of immunodeficient patients such as AIDS patients.
Conventionally, for oral candidiasis, antibiotics such as amphotericin B, dry syrups such as synthetic antifungal agents such as azoles, and gels have been developed. However, resistant bacteria and further drug resistant Candida -A new treatment is required due to the emergence and increase of bacterial species such as glabrata. In particular, therapies applicable to patients with extremely weak immunocompetence have not yet been established.
【0003】一方、植物精油の抗カンジダ活性（本発明にお
いてカンジダ菌に対する殺菌並びに静菌活性を抗カンジ
ダ活性という。）に関して、ハマーら（Ｋ．Ａ．Ｈａｍ
ｍｅｒ，Ｃ．Ｆ．Ｃａｒｓｏｎ，Ｊ．Ｖ．Ｒｉｌｅｙ：
Ｊ．Ａｎｔｉｍｉｃｒｏｂ．Ｃｈｅｍ．，４２，５９１
（１９９８））は、レモングラース油、タスマニアンラ
ベンダー油、ティートリー油およびフレンチラベンダー
油がそれぞれ０．１２％、０．２５％、０．２５％およ
び０．５％（W/V）の濃度で試験管内のＣａｎｄｉｄａ
ａｌｂｉｃａｎｓ ＡＴＣＣ１０２３１に有効と報告
しているが、バラ油やゼラニウム油、スパイクラベンダ
−油、パルマロ−ザ油に関しては報告が見当たらない。
また精油またはその主要成分が、口腔内の病原菌である
う蝕菌や周炎菌の除去作用、歯垢の減少効果や炎症の低
下作用があるという報告（特開平１０−２９８０９６
号）はあるが、口腔内のカンジダ症に有効であることを
示す報告はない。[0003] On the other hand, regarding the anti-Candida activity of plant essential oils (the bactericidal and bacteriostatic activity against Candida in the present invention is referred to as anti-Candida activity), Hammer et al.
mer, C.I. F. Carson, J .; V. Riley:
J. Antimicrob. Chem. , 42 , 591
(1998)) were lemon grass oil, tasmanian lavender oil, tea tree oil and french lavender oil at concentrations of 0.12%, 0.25%, 0.25% and 0.5% (W / V), respectively. Candida in a test tube
albicans ATCC 10231, but no report is found for rose oil, geranium oil, spike lavender oil, palmarosa oil.
Further, it is reported that the essential oil or its main component has an action of removing caries bacteria and peritonitis which are pathogenic bacteria in the oral cavity, an effect of reducing plaque and an effect of reducing inflammation (JP-A-10-298096).
No.), but there is no report showing that it is effective for oral candidiasis.
【0004】さらに、特開平１０−３３８６３０号にはシソ
油、ティートリー油、ラベンダー油、ゆず油、レモング
ラース油、タイム油、また、精油を含む植物片として青
シソ葉またはゆずの皮の精油および、精油の主要成分で
あるリモネン、リナリール・アセテート、リナロール、
ペリルアルデヒド、チトラール、カルバクロール、チモ
ール、ヒノキチオールを真菌感染拡散防止剤として使用
することが記載されている。[0004] Further, JP-A-10-338630 discloses perilla oil, tea tree oil, lavender oil, yuzu oil, lemongrass oil , thyme oil , and essential oils of green perilla leaves or yuzu peel as plant pieces containing essential oils and , Limonene, linalyl acetate, linalool, which are the main components of essential oils,
The use of perillaldehyde, citral, carvacrol, thymol, hinokitiol as fungal infection spreaders is described.
【0005】[0005]
【発明が解決しようとする課題】従って、口腔カンジダ
症の発症予防または治療のための安全性が高い、新規な
組成物を提供することが課題となっている。Therefore, it is an object to provide a novel composition having high safety for preventing or treating the onset of oral candidiasis.
【0006】[0006]
【課題を解決するための手段】本発明者らは鋭意研究の
結果、安全性が高く、比較的安価で簡便に使用できるハ
ーブの精油またはその主要な成分に、口腔カンジダ症の
発症予防または治療の効果を有するものを見出し、発明
を完成させた。本発明者らはまず口腔カンジダ菌に対す
る精油およびその成分の生体内での殺菌活性を、ソファ
エルら（Ｊ．Ａ．Ｓｏｆａｅｒ，Ｗ．Ｐ．Ｈｏｌｂｒｏ
ｏｋ，Ｊ．Ｃ．Ｓｏｕｔｈａｍ；Ａｒｃｈ．Ｏｒａｌ
Ｂｉｏｌ．，２７，４９７（１９８２））の方法に準拠
して作成した口腔カンジダ症モデルマウスを用いて調べ
た。すなわちＩＣＲマウスに、予めプレドニゾロン（１
００ｍｇ／ｋｇ）を皮下投与し、飲料水に塩酸テトラサ
イクリンを１ｍｇ／ｍｌで加えて飼育し、マウスの舌お
よび口腔内にカンジダ菌（Ｃａｎｄｉｄａ ａｌｂｉｃ
ａｎｓ ＴＩＭＭ２６４０）の１０６cells/匹を、麻酔
下マウスに接種する。接種３日後の観察で、マウスの舌
に口腔カンジダ症特有の白苔と組織の炎症が認められ、
マウス１匹あたり約１０５−１０６cellsのカンジダ菌
が口腔より回収され、口腔カンジダ症モデルの作成が確
認された。本発明者らは、このモデルマウスを用いて多
数の精油をスクリーニングした結果、口腔カンジダ症に
有効性を示す精油およびその主要成分を見いだして、本
発明に至った。Means for Solving the Problems As a result of intensive studies, the present inventors have found that the essential oil of an herb or its main component, which is highly safe, relatively inexpensive, and easy to use, prevents or treats the onset of oral candidiasis. The inventors have found ones that have the effect of, and completed the invention. The present inventors first demonstrated the in vivo bactericidal activity of essential oils and their components against oral Candida by the method of Sofaer et al. (JA Sofaer, WP Holbro).
ok, J. C. Southham; Arch. Oral
Biol. , 27 , 497 (1982)), and examined using an oral candidiasis model mouse. That is, prednisolone (1
(00 mg / kg) was subcutaneously administered, and tetracycline hydrochloride (1 mg / ml) was added to drinking water for breeding. Candida albic (Candida albic) was added to the tongue and oral cavity of mice.
ans TIMM2640) 10 6 cells / animal is inoculated into anesthetized mice. Observation 3 days after inoculation revealed white moss and tissue inflammation specific to oral candidiasis on the tongue of mice,
About 10 5 -10 6 cells of Candida per mouse were recovered from the oral cavity, and the creation of an oral candidiasis model was confirmed. As a result of screening a large number of essential oils using this model mouse, the present inventors have found the essential oils and their main components that are effective against oral candidiasis, and arrived at the present invention.
【0007】[0007]
【発明の実施の形態】本願において精油とは、種々の植
物片から主に水蒸気蒸留または圧搾によって得られた芳
香性油状物をいう。本発明は、精油またはその主要な成
分を水に懸濁し、あるいは油に溶解して、患部に直接塗
布、うがいなどの方法、また飲食物に添加して患部に接
触させることによって口腔カンジダ症を予防および治療
することを特徴とする。使用できる精油としては、ティ
ートリー油、ゼラニウム油、バラ油、フレンチラベンダ
ー油、真正ラベンダー油、スパイクラベンダー油、タイ
ム油、ペパーミント油、スペアーミント油、パチュリー
油、レモングラース油、サンダルウッド油、タイム油、
パルマローザ油などがあげられる。BEST MODE FOR CARRYING OUT THE INVENTION In the present application, the essential oil means an aromatic oily substance obtained mainly from various plant pieces by steam distillation or pressing. The present invention, the essential oil or its main components are suspended in water, or dissolved in oil, directly applied to the affected area, a method such as gargling, or by adding to the food or drink to contact the affected area oral candidiasis It is characterized by preventing and treating. Essential oils that can be used are tea tree oil, geranium oil, rose oil, French lavender oil, genuine lavender oil, spiked lavender oil, thyme oil, peppermint oil, spearmint oil, patchouli oil, lemon grass oil, sandalwood oil, thyme oil. ,
Examples include palmarosa oil.
【0008】精油の主要成分としては、テルピネン−４−オ
ール、リナロール、シトロネロール、ゲラニオール、シ
トラール、シトロネラール、ヒノキチオールなどがあげ
られる。本発明では、精油単独でも使用可能であるが、
種々の精油のブレンドや他の抗真菌剤との併用も可能で
ある。精油は古来から人に安全に使用されてきている。
ハーブとして食用に供され、ハ−ブティーとして飲用さ
れてきた。また、アロマテラピーにおいても、内服や皮
膚への投与が支障なく行われており、安全に使用するた
めの指針もまとめられいる（ロバート ティスランド／
トニー・ハラシュ著（高林林太郎訳）：精油の安全性
ガイド、上、下、フレグランスジャーナル社、１９９７
年）。[0008] Examples of the main components of the essential oil include terpinen-4-ol, linalool, citronellol, geraniol, citral, citronellal, and hinokitiol. In the present invention, the essential oil can be used alone,
Blends of various essential oils and combinations with other antifungal agents are also possible. Essential oils have been safely used by humans since ancient times.
It has been used as an herb for food and as a herb tea. In aromatherapy, oral administration and administration to the skin are performed without any problems, and guidelines for safe use are also summarized (Robert Tisland /
Tony Harash (Translated by Hayashi Taro Hayashi): Essential Oil Safety Guide, Top, Bottom, Fragrance Journal, 1997
Year).
【0009】使用濃度と期間は精油の種類、症状の程度で異
なるが、通常０．１−１０％（W/W）の精油またはその
主要な有効成分を、１日１回から３回、１週間ないしそ
れ以上の期間適用するのが好ましい。投与形態は経口投
与が主であるが、外用として、含嗽・洗口剤に、または
皮膚に塗り込むことも可能である。経口で投与する場合
は、錠剤、トローチとして製剤化するのがよい。また、
塗り薬とする場合はチンキ剤、ゲル化剤、軟膏などとし
て使用するのがよい。さらに、飲食品に添加することに
より予防用の飲食品として使用することも可能である。
例えば、ハードキャンデーやゼリー飲料として用いられ
る。[0009] The concentration and period of use differ depending on the type of essential oil and the degree of symptoms, but usually 0.1-10% (W / W) of essential oil or its main active ingredient is used once to three times a day. It is preferably applied for a period of weeks or more. The dosage form is mainly oral administration, but it can also be applied externally to a mouthwash / mouthwash or to the skin. When administered orally, it is better to formulate it as a tablet or troche. Also,
When used as a ointment, it is preferably used as a tincture, a gelling agent, an ointment and the like. Furthermore, it can be used as a preventive food or drink by adding it to the food or drink.
For example, it is used as a hard candy or a jelly drink.
【0010】[0010]
【実施例】本発明を以下の実施例によりさらに詳細に説
明するが、本発明はこれらの実施例に限定されるもので
はない。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.
【0011】実施例１
ＩＣＲマウス（８週齢雌、平均体重２３ｇ）に、予めプ
レドニゾロン（１００ｍｇ／ｋｇ）を皮下投与し、飲料
水に塩酸テトラサイクリンを１ｍｇ／ｍｌで加えて１日
飼育した後、マウスの口腔内にカンジダ菌（Ｃａｎｄｉ
ｄａ ａｌｂｉｃａｎｓ ＴＩＭＭ２６４０）の１０６
cellsを接種した。その際、マウス腹腔内にネンブター
ル麻酔剤（投与量は50mg/kg）を投与し、安静にさせ
た。接種後３及び２４時間後に、精油または、その成分
５０μｌを口腔内に塗布した。４８時間後に舌の状態を
観察し、感染の重症度を評価、記録した。そのスコア化
は、下記にしたがい５段階の評価に分けた。 Example 1 ICR mice (8-week-old female, average weight 23 g) were subcutaneously pre-administered with prednisolone (100 mg / kg) in advance, and tetracycline hydrochloride (1 mg / ml) was added to drinking water and the animals were bred for 1 day. Candida (Candi) in the mouth of mice
da albicans TIMM 2640) 10 6
cells were inoculated. At that time, a Nembutal anesthetic (dose: 50 mg / kg) was intraperitoneally administered to the mouse and allowed to rest. 3 and 24 hours after the inoculation, 50 μl of essential oil or its component was applied to the oral cavity. After 48 hours, the condition of the tongue was observed, and the severity of infection was evaluated and recorded. The scoring was divided into 5 grades according to the following.
【0012】スコア
０点：異常が認められない。
１点：舌表面の５％未満の範囲で赤い炎症又は白苔様の
白い異物が認められる。
２点：舌表面の５％以上９０％未満の範囲で白苔様の白
い異物が認められる。なお舌表面に陥没又は隆起などの
面構造の異常は認められない。
３点：舌表面の５％以上９０％未満の範囲で白苔様の白
い異物が認められる。更に舌表面に陥没又は隆起などの
面構造の異常が認められる。
４点：舌表面の９０％以上の範囲で白苔様の白い異物が
認められる。その白苔を取ると舌表面に陥没又は隆起な
どの面構造の異常が認められる。[0012] Score 0: No abnormality is recognized. 1 point: Red inflammation or white moss-like white foreign matter was observed in an area of less than 5% of the surface of the tongue. 2 points: White moss-like white foreign matter is observed in the range of 5% to less than 90% of the tongue surface. No abnormalities in the surface structure such as depressions or bumps were found on the tongue surface. 3 points: White moss-like white foreign matter is observed in the range of 5% to less than 90% of the tongue surface. Furthermore, surface structure abnormalities such as depressions or protrusions are recognized on the tongue surface. 4 points: White moss-like white foreign matter is observed in an area of 90% or more of the tongue surface. When the white moss is removed, abnormalities in the surface structure such as depressions or bumps are observed on the tongue surface.
【0013】さらにマウスの口腔内を１ｍｌの生理食塩水で
洗浄し、カンジダ菌を回収した。回収した菌液は生理食
塩水で希釈し、カンジダＧＳ寒天培地に塗布し、２４時
間培養し、コロニーを形成させ生菌数を求めた。精油希
釈液の代わりに１％ツイーン８０含有生理食塩水で洗っ
た対照群では、約１０６cellsの生菌が回収された。各
群の生菌数を、対照群に比べ、抗菌活性を以下のように
表すことにした。
（−）:対照群と差のないもの
（＋）：生菌数が対照群の１/１０を越えて１/５以下
（＋＋）：生菌数が対照群の１/１００を越えて１/１０
以下
（＋＋＋）：生菌数が対照群の1/１００以下
表１に、１群５匹のマウスを用いて、ミルラ精油希釈液
とティートリー精油希釈液の効果を調べた結果を示す。
なお、各精油は、１％ツイーン８０含有生理食塩水で10
％（W/W）になるように希釈した。表１から分かるよう
にミルラ精油希釈液では、感染を防御しなかったが、テ
ィートリー精油希釈液の場合には、舌の症状が改善さ
れ、菌数も１／１０以下に低下し抗菌作用があることが
わかった。[0013] Further, the inside of the mouth of the mouse was washed with 1 ml of physiological saline to recover Candida. The collected bacterial solution was diluted with physiological saline, applied on Candida GS agar medium and cultured for 24 hours to form colonies, and the viable cell count was determined. In the control group, which was washed with a physiological saline solution containing 1% Tween 80 instead of the diluted essential oil solution, about 10 6 viable cells were recovered. The number of viable bacteria in each group was compared with that in the control group, and the antibacterial activity was expressed as follows. (-): No difference from control group (+): Viable cell count exceeds 1/10 of control group and 1/5 or less (++): Viable cell count exceeds 1/100 of control group and 1 / 10
Below (+++): the viable cell count is 1/100 or less of the control group. Table 1 shows the results of examining the effects of the myrrh essential oil diluted solution and the tea tree essential oil diluted solution using 5 mice per group.
Each essential oil is 10% in saline containing 1% Tween 80.
It diluted so that it might become% (W / W). As can be seen from Table 1, the myrrh essential oil diluted solution did not protect against infection, but in the case of tea tree essential oil diluted solution, the tongue symptom was improved, and the number of bacteria decreased to 1/10 or less, and there was an antibacterial action. I understood it.
【0014】[0014]
【表１】 [Table 1]
【0015】実施例２
実施例１と同様な方法で、レモングラース精油の主な構
成物質であるシトラールの１０％液及びシナモンバーグ
油の主要構成物質シンナムアルデヒドの１０％液を同様
に検討した。結果を表２に示す。ここでわかるようにシ
トラールは治療効果を発揮するのに対し、シンナムアル
デヒドはほとんど無効であった。 Example 2 In the same manner as in Example 1, a 10% solution of citral, which is a main constituent of lemongrass essential oil, and a 10% solution of cinnamaldehyde, a main constituent of cinnamon burg oil, were similarly examined. The results are shown in Table 2. As can be seen, citral exerted a therapeutic effect, whereas cinnamaldehyde was largely ineffective.
【0016】[0016]
【表２】 [Table 2]
【0017】実施例３
実施例１と同様な方法で、真性ラベンダー油、フレンチ
ラベンダー油、スパイクラベンダー油、バラ油、ゼラニ
ウム油、パチュリー油、タイム油及びパルマローザ油の
４％液の効果を同様に検討した。結果を表３に示す。こ
れより、いずれの精油も効果があるが、とくに、バラ
油、ゼラニウム油、タイム油及びパルマローザ油が、強
い治療効果を発揮することが示された。 Example 3 In the same manner as in Example 1, the effect of a 4% liquid of genuine lavender oil, French lavender oil, spiked lavender oil, rose oil, geranium oil, patchouli oil, thyme oil and palmarosa oil was similarly obtained. investigated. The results are shown in Table 3. From these results, it was shown that all essential oils are effective, but especially rose oil, geranium oil, thyme oil and palmarosa oil exert a strong therapeutic effect.
【0018】[0018]
【表３】 [Table 3]
【0019】実施例４
実施例１と同様な方法で、ティートリー油の主な構成物
質であるテルピネン−４−オール、パルマローザ油の主
な構成物質であるゲラニオール、レモングラース精油の
主な構成物質であるシトラール、ローズ油の主な構成物
質であるシトロネロールの各４％液を同様に検討した。
結果を表４に示す。これより、いずれのテルペノイドも
治療効果を発揮しうるが、とくに、ゲラニオールとシト
ロネロールが、強い治療効果を発揮することがわかっ
た。 Example 4 In the same manner as in Example 1, terpinen-4-ol, which is a main constituent of tea tree oil, geraniol, which is a main constituent of palmarosa oil, and main constituents of lemon grass essential oil. A 4% solution of each of citral and citronellol, which is a main constituent of rose oil, was examined in the same manner.
The results are shown in Table 4. From this, it was found that both terpenoids could exert a therapeutic effect, but especially geraniol and citronellol exert a strong therapeutic effect.
【0020】[0020]
【表４】 [Table 4]
【0021】製剤例1
基材の作成：チンキ製剤として、パルマローザ油４ｍｌ
を、エタノールを含む注射用精製水９６ｍｌに加え、攪
拌しチンキ製剤１００ｍｌを作製した。 Formulation Example 1 Preparation of base material: as a tincture formulation, 4 ml of palmarosa oil
Was added to 96 ml of purified water for injection containing ethanol and stirred to prepare 100 ml of a tincture preparation.
【0022】製剤例2
基材の作成：軟膏基剤１００ｇにゼラニウム精油４ｍｌ
を加え、ゼラニウム精油軟膏１０４ｇを作製した。 Formulation Example 2 Preparation of base material: 100 g of ointment base and 4 ml of geranium essential oil
Was added to prepare 104 g of geranium essential oil ointment.
【0023】製剤例3
基材の作成：ｂｅｔａサイクロデキストリン１ｇを水１
００ｍｌに溶解し、バラ油２００ｍｇのエタノ−ル溶液
を加えて室温で激しく攪拌する。５時間後にバラ油を包
接したｂｅｔａサイクロデキストリンを濾過して採取
し、室温で乾燥して、水溶性の製剤を得た。 Formulation Example 3 Preparation of base material: beta cyclodextrin 1 g water 1
It is dissolved in 00 ml, 200 mg of rose oil in ethanol is added, and the mixture is vigorously stirred at room temperature. After 5 hours, the beta cyclodextrin in which rose oil was included was collected by filtration and dried at room temperature to obtain a water-soluble preparation.
【0024】製造例1
グラニュー糖５０．７重量部、水飴４８．８重量部、ク
エン酸０．３重量部、香料０．１重量部、バラ油０．１
重量部、ゼラニウム油０．１重量部の配合で常法に従い
ハードキャンディを製造した。 Production Example 1 Granulated sugar 50.7 parts by weight, starch syrup 48.8 parts by weight, citric acid 0.3 parts by weight, perfume 0.1 parts by weight, rose oil 0.1
A hard candy was produced according to a conventional method with the addition of 0.1 part by weight of geranium oil.
【0025】製造例2
水飴４１．８重量部、グラニュー糖１５．５重量部、粉
糖４．０重量部、ペクチン２．３重量部、クエン酸０．
２５重量部、香料０．１５重量部、タイム油０．１重量
部、パルマローザ油０．１重量部、水３５．８重量部を
用いて常法によりゼリー飲料を製造した。 Production Example 2 41.8 parts by weight of starch syrup, 15.5 parts by weight of granulated sugar, 4.0 parts by weight of powdered sugar, 2.3 parts by weight of pectin, 0.1 part of citric acid.
A jelly beverage was produced by a conventional method using 25 parts by weight, 0.15 parts by weight of fragrance, 0.1 part by weight of thyme oil, 0.1 part by weight of palmarosa oil, and 35.8 parts by weight of water.
【0026】[0026]
【発明の効果】本発明は、精油またはその主要成分を使
用することにより、口腔カンジダ症を予防ないし治療す
る、安全性の高い抗口腔カンジダ症組成物を提供するこ
とができる。INDUSTRIAL APPLICABILITY The present invention can provide a highly safe anti-oral candidiasis composition which prevents or treats oral candidiasis by using an essential oil or a main component thereof.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ２３Ｌ 1/30 Ａ２３Ｌ 1/30 Ｂ Ａ６１Ｋ 7/00 Ａ６１Ｋ 7/00 Ｃ Ｋ 7/16 7/16 7/26 7/26 31/045 31/045 31/121 31/121 31/122 31/122 Ａ６１Ｐ 1/02 Ａ６１Ｐ 1/02 31/10 31/10 (72)発明者 滝沢 登志雄 埼玉県坂戸市千代田５−３−１ 明治製菓 株式会社食料総合研究所内 Ｆターム(参考） 4B018 LB01 LB08 LE01 LE04 MD07 MD08 MD48 MD61 MD66 ME09 MF01 4C083 AA111 AA112 AC081 AC082 AC091 AC092 AC102 AC211 AC212 AD252 BB41 CC41 DD15 DD16 DD17 DD22 DD23 DD27 DD28 DD41 EE09 EE31 4C088 AB38 AB55 AB57 AB73 BA18 CA02 CA05 CA15 MA02 MA07 MA08 MA17 MA22 MA23 MA28 MA35 MA36 MA41 MA43 MA52 MA57 MA63 NA06 NA14 ZA67 ZB37 4C206 AA01 AA02 CA08 CA10 CB02 CB18 KA01 MA01 MA04 MA37 MA42 MA43 MA48 MA55 MA56 MA61 MA63 MA72 MA77 MA83 NA06 NA14 ZA67 ZB37 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A23L 1/30 A23L 1/30 B A61K 7/00 A61K 7/00 C K 7/16 7/16 7 / 26 7/26 31/045 31/045 31/121 31/121 31/122 31/122 A61P 1/02 A61P 1/02 31/10 31/10 (72) Inventor Toshio Takizawa 5-Chiyoda, Sakado, Saitama Prefecture 3-1 Meiji Seika Co., Ltd. Food Research Institute F Term (reference) 4B018 LB01 LB08 LE01 LE04 MD07 MD08 MD48 MD61 MD66 ME09 MF01 4C083 AA111 AA112 AC081 AC082 AC091 AC092 AC102 AC211 AC212 AD252 BB41 CC41 DD15 DD16 DD17 DD22 DD41 DD27 DD28 DD28 DD27 DD28 DD28 DD27 DD28 EE31 4C088 AB38 AB55 AB57 AB73 BA18 CA02 CA05 CA15 MA02 MA07 MA08 MA17 MA22 MA23 MA28 MA35 MA36 MA41 MA43 MA52 MA57 MA63 NA06 NA14 ZA67 ZB37 4C206 AA01 AA02 CA08 CA10 CB02 CB18 KA01 MA01 MA04 MA37 MA42 MA43 MA48 MA48 MA48 MA48 MA48 MA61 MA63 MA72 MA77 MA83 NA06 NA14 ZA67 ZB37
Claims (6)
として含有する、口腔カンジダ症の予防および治療のた
めの抗口腔カンジダ症医薬組成物。1. An anti-oral candidiasis pharmaceutical composition for preventing and treating oral candidiasis, which comprises one or more kinds of essential oils or components thereof as an active ingredient.
油、フレンチラベンダー油、スパイクラベンダー油、バ
ラ油、ゼラニウム油、パチュリー油、レモングラース
油、パルマローザ油である、請求項１に記載の抗口腔カ
ンジダ症医薬組成物。2. The anti-oral candidiasis according to claim 1, wherein the essential oil is tea tree oil, authentic lavender oil, french lavender oil, spike lavender oil, rose oil, geranium oil, patchouli oil, lemon grass oil, palmarosa oil. Pharmaceutical composition.
ロール、シトロネロール、ゲラニオール、シトラール、
シトロネラール、ヒノキチオールである、請求項１に記
載の抗口腔カンジダ症医薬組成物。3. The essential oil component is terpinen-4-ol, linalool, citronellol, geraniol, citral,
The anti-oral candidiasis pharmaceutical composition according to claim 1, which is citronellal or hinokitiol.
飲食品。4. A food or drink containing one or more kinds of essential oil or its components.
油、フレンチラベンダー油、スパイクラベンダー油、バ
ラ油、ゼラニウム油、パチュリー油、レモングラース
油、パルマローザ油である、請求項４に記載の飲食品。5. The food or drink according to claim 4, wherein the essential oil is tea tree oil, authentic lavender oil, French lavender oil, spike lavender oil, rose oil, geranium oil, patchouli oil, lemon grass oil, palmarosa oil.
ロール、シトロネロール、ゲラニオール、シトラール、
シトロネラール、ヒノキチオールである、請求項４に記
載の飲食品。6. The essential oil component is terpinen-4-ol, linalool, citronellol, geraniol, citral,
The food or drink according to claim 4, which is citronellal or hinokitiol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001286088A JP2003089652A (en) | 2001-09-20 | 2001-09-20 | Anti oral cavity candidiasis composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001286088A JP2003089652A (en) | 2001-09-20 | 2001-09-20 | Anti oral cavity candidiasis composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003089652A true JP2003089652A (en) | 2003-03-28 |
Family
ID=19109127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001286088A Pending JP2003089652A (en) | 2001-09-20 | 2001-09-20 | Anti oral cavity candidiasis composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003089652A (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1545448A4 (en) * | 2002-08-27 | 2005-12-14 | Wrigley W M Jun Co | Breath freshening and oral cleansing product using geraniol |
| JP2006169217A (en) * | 2004-12-20 | 2006-06-29 | Hatsuichi Shiba | Antifungal agent |
| JP2006241051A (en) * | 2005-03-02 | 2006-09-14 | Pokka Corp | Anti-stress agent |
| JP2006273824A (en) * | 2005-03-30 | 2006-10-12 | Kobayashi Pharmaceut Co Ltd | Oral composition for promoting evacuation containing patchouli oil and dietary fiber |
| JP2006298824A (en) * | 2005-04-21 | 2006-11-02 | Kao Corp | Inhibitor for skatole production in oral cavity |
| WO2006129876A1 (en) * | 2005-05-31 | 2006-12-07 | Kanebo Foods, Ltd. | Body odor improving agent for ingestion into body, beverage/food using the same, and method for improvement body odor |
| JP2008036343A (en) * | 2006-08-10 | 2008-02-21 | Norio Hosoi | Oral wetting agent, and denture adhesive |
| JP2008044861A (en) * | 2006-08-11 | 2008-02-28 | En Otsuka Pharmaceutical Co Ltd | Aspiration pneumonia-preventing agent |
| KR100886494B1 (en) * | 2006-03-07 | 2009-03-05 | 롯데제과주식회사 | Methioninase inhibitor, oral composition and foods which containing it |
| JP2009280573A (en) * | 2008-04-23 | 2009-12-03 | Daiichi Sankyo Healthcare Co Ltd | Body odor inhibitor for internal use |
| US8012967B2 (en) | 2006-09-30 | 2011-09-06 | University Of Strathclyde | Minor groove binders |
| JP2012072179A (en) * | 2005-08-30 | 2012-04-12 | Kao Corp | Biofilm inhibitor |
| US8372452B2 (en) | 2008-06-26 | 2013-02-12 | Piramal Life Sciences Limited | Oral herbal composition for the treatment of oral candidiasis |
| JP2013040156A (en) * | 2011-08-11 | 2013-02-28 | Shigeru Abe | New composition having anticandidal activity |
| WO2016174112A1 (en) * | 2015-04-29 | 2016-11-03 | O'brien Sean Liam | Odontalgic preparation |
| WO2017038872A1 (en) * | 2015-08-31 | 2017-03-09 | 和興フィルタテクノロジー株式会社 | Composition having antifungal activity |
| JPWO2016039229A1 (en) * | 2014-09-12 | 2017-04-27 | マルハニチロ株式会社 | Antifungal composition containing antifungal peptide and terpene alcohol |
| KR20180087717A (en) | 2017-01-25 | 2018-08-02 | 영남대학교 산학협력단 | Composition for inhibiting biofilm formation of fungi |
| CN110885717A (en) * | 2019-12-16 | 2020-03-17 | 株洲千金药业股份有限公司 | Natural antibacterial detergent for lady clothes |
| CN111700825A (en) * | 2020-06-29 | 2020-09-25 | 上海中医药大学 | Oily composition for oral health care, preparation method and application thereof |
-
2001
- 2001-09-20 JP JP2001286088A patent/JP2003089652A/en active Pending
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1545448A4 (en) * | 2002-08-27 | 2005-12-14 | Wrigley W M Jun Co | Breath freshening and oral cleansing product using geraniol |
| JP2006169217A (en) * | 2004-12-20 | 2006-06-29 | Hatsuichi Shiba | Antifungal agent |
| JP2006241051A (en) * | 2005-03-02 | 2006-09-14 | Pokka Corp | Anti-stress agent |
| JP2006273824A (en) * | 2005-03-30 | 2006-10-12 | Kobayashi Pharmaceut Co Ltd | Oral composition for promoting evacuation containing patchouli oil and dietary fiber |
| JP2006298824A (en) * | 2005-04-21 | 2006-11-02 | Kao Corp | Inhibitor for skatole production in oral cavity |
| JPWO2006129876A1 (en) * | 2005-05-31 | 2009-01-08 | クラシエフーズ株式会社 | Body odor improving agent for ingestion into body, food and drink using the same, and body odor improving method |
| JP5890083B2 (en) * | 2005-05-31 | 2016-03-22 | クラシエフーズ株式会社 | Body odor improving agent for ingestion in body, food and drink using the same, and method for improving body odor |
| WO2006129876A1 (en) * | 2005-05-31 | 2006-12-07 | Kanebo Foods, Ltd. | Body odor improving agent for ingestion into body, beverage/food using the same, and method for improvement body odor |
| JP2015221792A (en) * | 2005-05-31 | 2015-12-10 | クラシエフーズ株式会社 | Body odor improving agent for ingestion into body, beverage/food using the same, and method for improving body odor |
| JP2012072179A (en) * | 2005-08-30 | 2012-04-12 | Kao Corp | Biofilm inhibitor |
| KR100886494B1 (en) * | 2006-03-07 | 2009-03-05 | 롯데제과주식회사 | Methioninase inhibitor, oral composition and foods which containing it |
| JP2008036343A (en) * | 2006-08-10 | 2008-02-21 | Norio Hosoi | Oral wetting agent, and denture adhesive |
| JP2008044861A (en) * | 2006-08-11 | 2008-02-28 | En Otsuka Pharmaceutical Co Ltd | Aspiration pneumonia-preventing agent |
| US8012967B2 (en) | 2006-09-30 | 2011-09-06 | University Of Strathclyde | Minor groove binders |
| JP2009280573A (en) * | 2008-04-23 | 2009-12-03 | Daiichi Sankyo Healthcare Co Ltd | Body odor inhibitor for internal use |
| US8372452B2 (en) | 2008-06-26 | 2013-02-12 | Piramal Life Sciences Limited | Oral herbal composition for the treatment of oral candidiasis |
| JP2013040156A (en) * | 2011-08-11 | 2013-02-28 | Shigeru Abe | New composition having anticandidal activity |
| CN110075271A (en) * | 2014-09-12 | 2019-08-02 | 玛鲁哈日鲁株式会社 | Antifungal composition containing anti-fungus peptide and terpenol |
| JPWO2016039229A1 (en) * | 2014-09-12 | 2017-04-27 | マルハニチロ株式会社 | Antifungal composition containing antifungal peptide and terpene alcohol |
| CN107073064A (en) * | 2014-09-12 | 2017-08-18 | 玛鲁哈日鲁株式会社 | Antifungal composition containing anti-fungus peptide and terpenol |
| WO2016174112A1 (en) * | 2015-04-29 | 2016-11-03 | O'brien Sean Liam | Odontalgic preparation |
| WO2017038872A1 (en) * | 2015-08-31 | 2017-03-09 | 和興フィルタテクノロジー株式会社 | Composition having antifungal activity |
| CN108025043A (en) * | 2015-08-31 | 2018-05-11 | 和兴滤清器科技株式会社 | Composition with antifungal activity |
| US10729779B2 (en) | 2015-08-31 | 2020-08-04 | Wako Filter Technology Co., Ltd. | Composition having antifungal activity |
| CN108025043B (en) * | 2015-08-31 | 2021-11-05 | 和兴滤清器科技株式会社 | Composition with antifungal activity |
| US11344625B2 (en) | 2015-08-31 | 2022-05-31 | Wako Filter Technology Co., Ltd. | Compositions having antifungal activity |
| KR20180087717A (en) | 2017-01-25 | 2018-08-02 | 영남대학교 산학협력단 | Composition for inhibiting biofilm formation of fungi |
| CN110885717A (en) * | 2019-12-16 | 2020-03-17 | 株洲千金药业股份有限公司 | Natural antibacterial detergent for lady clothes |
| CN111700825A (en) * | 2020-06-29 | 2020-09-25 | 上海中医药大学 | Oily composition for oral health care, preparation method and application thereof |
| CN111700825B (en) * | 2020-06-29 | 2022-07-01 | 上海中医药大学 | Oily composition for oral health care, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003089652A (en) | Anti oral cavity candidiasis composition | |
| US10195239B2 (en) | Extract of Trigonella foenum-graecum | |
| WO1999034811A1 (en) | Anti-fungal compositions with prolonged activity | |
| CN109890955A (en) | It is resistant to the lactic acid bacteria of antibacterial agent | |
| EP1649864B1 (en) | Periodontal disease therapeutic and/or preventive composition | |
| CN106794210A (en) | Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition | |
| WO2018062605A1 (en) | Toothpaste composition containing galenical extract | |
| KR20190000955A (en) | Composition for preventing or treating periodontal disease comprising extracts of herbal mixture | |
| WO2005091937A2 (en) | Compositions useful for the treatment of microbial infections | |
| CN112263606A (en) | Traditional Chinese medicine gargle and preparation method thereof | |
| CN101181208B (en) | Gargle containing natural antibiotics and preparation method thereof | |
| KR101033921B1 (en) | Composition for reducing irritation and inflammation in skin | |
| KR101576352B1 (en) | Pharmaceutical composition comprising extract of lycium root bark as an effective ingredient for the prevention or the treatment of the periodontitis diseases | |
| KR102594674B1 (en) | Oral composition comprising herbal complex | |
| KR100807842B1 (en) | Anti-fungal composition for deodorization | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| KR20190080504A (en) | Composition for the prevention and improvement of Periodontal Disease | |
| CN111481474A (en) | Mouth cleaning liquid and preparation method thereof | |
| Sneha et al. | Bactericidal activity of ayurvedic formulation against cariogenic microorganisms | |
| RU2618889C1 (en) | Mouthwash agent having antiinflammatory, antimicrobial, wound-healing effect | |
| CN110013452A (en) | Permanent tooth shield gum is cured the Chinese medicine compound prescription toothpaste and preparation method thereof of ulcer and dark hair | |
| KR101834758B1 (en) | Composition containing a bee venom for prevention or treating periodontal diseases | |
| KR102557352B1 (en) | Composition for Preventing or Treating Periodontal Disease Comprising Extracts of Rosa davurica Pall as Active Ingredient | |
| KR101671057B1 (en) | Pharmaceutical composition comprising extract of ligustri fructus and extract of lycium root bark as an effective ingredient for the prevention or the treatment of the periodontitis diseases | |
| CN114601760A (en) | Oral composition |